Physician profile
Michael Epps
NPI 1386273472
$988.07
in general payments reported to CMS, 2019-2025
12 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.59 · 2022: $38.81 · 2023: $115 · 2024: $313 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $216.30 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $164.97 | 2021-2025 | Hydrus Microstent, Argos, Clareon |
| Rxsight INC | $142.62 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Abbvie INC. | $114.42 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $96.15 | 2023 | Eylea Hd |
| Harrow Eye, LLC | $63.68 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $62.70 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $42.98 | 2024-2025 | Miebo, Xiidra |
| Dompe US, INC. | $27.49 | 2025 | Oxervate |
| Lilly USA, LLC | $26.54 | 2024 | Mounjaro |
| Glaukos Corporation | $15.79 | 2025 | Istent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Epps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.